June 2026 Research Update

Across these papers, a common pattern was that testing can identify Fabry-related gene variants in people without clear symptoms yet, but deciding what those variants mean is not always straightforward. Studies also emphasized that diagnosis is stronger when genetic results are interpreted alongside other information, such as blood markers, X-chromosome biology in females, and careful heart imaging, because single tests can mislead. [1] [2] [3] [4]

In a large Japanese newborn screening program (782,591 newborns screened), screening found 29 different gene variants in 77 newborns, including both pathogenic variants and variants of uncertain significance (meaning their health impact is unclear). Five male newborns with pathogenic variants later developed Fabry-related signs and started enzyme replacement therapy, showing that some children identified by screening can develop recognizable disease features during follow-up. The report also provided frequency estimates that were higher when variants of uncertain significance were counted together with pathogenic variants. [1]

In an observational study of 51 untreated females with Fabry-related gene changes, combining several measures helped separate different clinical patterns: X-chromosome inactivation (how much the working copy of the gene is turned off), alpha-galactosidase A activity in blood cells and plasma, and plasma lysoGb3. The authors reported that the ratio of enzyme activity to lysoGb3, considered together with X-chromosome inactivation, best distinguished classic Fabry, later-onset Fabry, and a group described as AGALopathic variants, where biomarker patterns differed from the other groups. This was a cross-sectional study, so it cannot show how well these measures predict future symptoms in an individual person. [2]

Two case reports focused on Fabry-like heart findings and how diagnosis can be missed or confused. One man in his 50s was initially thought to have hypertrophic cardiomyopathy based on thickened heart muscle and later developed heart failure before genetic testing identified a GLA gene variant consistent with Fabry disease; his heart scan showed extensive scarring, and a heart biopsy did not provide the diagnosis. Another report described how a heart scan measurement could look Fabry-like due to contrast contamination, leading to an initial incorrect impression before the picture was clarified as true hypertrophic cardiomyopathy. [3] [4]

For patients and caregivers, this set of studies mainly adds context about why Fabry diagnosis and screening can take time and why results can be uncertain, especially when a gene change is labeled as uncertain or when a person (often a female) has mixed lab signals. The newborn screening report suggests that screening can identify some people before symptoms, but also highlights that follow-up is needed because not everyone with a detected variant develops clear signs quickly, and some variants are difficult to classify. The female biomarker study suggests that combining multiple lab measures may help interpret risk and type of Fabry in females, but this approach still needs validation in broader and longer-term follow-up. The heart case reports underline that Fabry can be confused with other causes of heart thickening and that imaging quality and interpretation can affect conclusions. [1] [2] [3] [4]

Across this group of papers, kidney involvement in Fabry disease looked highly variable, even among relatives with the same genetic change, and kidney decisions often depended on how early and how clearly Fabry-related kidney damage was identified. The evidence ranged from guidelines and a survey to small case reports and small case series, so conclusions about outcomes are limited. Still, multiple reports described enzyme replacement therapy lowering Fabry blood markers while kidney outcomes ranged from stable kidney function to progression despite treatment. [5] [6] [7]

An evidence-based guideline from the Korean Society of Nephrology focused on Fabry-related kidney disease and highlighted early diagnosis and timely treatment discussions, including enzyme replacement therapy and chaperone therapy as options considered in care. It was structured around 11 key clinical questions using the GRADE approach, aiming to standardize decision-making in Fabry nephropathy. [5]

In a single-family series of seven relatives carrying the same GLA variant, kidney disease ranged from preserved kidney function to severe chronic kidney disease, and biopsies in affected relatives showed Fabry-typical storage changes with some chronic damage. All received enzyme replacement therapy, but kidney responses differed: some stabilized or improved while one person progressed to dialysis and later died. The authors noted that female relatives could have mild or even subclinical kidney involvement, and family screening identified additional affected members. [7]

A small national case series described two adult men who had previously received kidney transplants and then started enzyme replacement therapy (agalsidase beta or agalsidase alfa). In both, the Fabry blood marker lyso-Gb3 decreased over 12 months and the transplanted kidney function remained stable without protein in the urine; heart findings also did not worsen over the reported follow-up. One person had improved nerve pain and quality of life measures, while the other had ongoing and later ischemic brain-related problems despite biochemical improvement, suggesting some advanced nerve or brain problems may not reverse. [6]

One case report described a 17-year-old girl with heavy protein in the urine who was diagnosed with Fabry disease along with idiopathic multicentric Castleman disease and membranous nephropathy. Steroid treatment rapidly reduced protein in the urine and inflammation markers, and later enzyme replacement therapy was reported to keep lyso-Gb3 low and protein in the urine from returning during follow-up. The report also highlighted that Fabry enzyme activity in blood testing was normal despite a disease-causing genetic change, underscoring that diagnosis can require multiple types of tests in some situations. [8]

A cross-sectional survey in South Korea found that patients and kidney doctors generally prioritized diagnostic accuracy, but patients more often emphasized discomfort and perceived risks of testing procedures. The survey also showed a gap in expectations about kidney-protective medicines: most clinicians believed these medicines protect the kidneys, while fewer patients were willing to accept them without strong evidence. Both patients and clinicians expressed a preference for oral (rather than injectable) enzyme-related treatment formats, and there was shared agreement on the importance of genetic counseling for family screening. [9]

For patients and caregivers, this set of studies mainly reinforces that Fabry-related kidney disease can look very different from person to person, even within the same family, and that monitoring may include a mix of urine tests, blood markers, genetic testing, and sometimes kidney biopsy in complex cases. The small transplant and case-report data suggest enzyme replacement therapy can lower Fabry blood markers and may coincide with stable kidney measures in some people, but they do not prove the same result will happen broadly or over decades. The survey highlights that communication gaps can exist around why certain kidney-protection steps are recommended and what evidence patients expect, which may affect shared decision-making and comfort with testing and long-term plans. Uncertainty remains about which factors best predict who will progress, who will stabilize, and how much advanced non-kidney symptoms can improve once present. [5] [8] [6] [7] [9]

Across these papers, a consistent message is that heart problems in Fabry disease are not one-size-fits-all, and risk prediction may work best when it combines several types of information. Studies highlighted the role of sex, specific gene variants, heart rhythm tests, heart imaging changes (including scarring), and blood markers, with some results suggesting common cardiovascular risk factors can strongly shape how disease shows up. [10] [11] [12]

A cohort study proposed grouping people into four heart-related patterns based on test results: abnormal electrocardiogram (ECG), higher heart blood markers, heart muscle thickening, and scarring on a heart scan. In this study, the gene variant type and sex were linked to a combined outcome that included cardiac hospitalization, device implantation, or cardiovascular or cerebrovascular death, and scarring on heart imaging was tied to higher risk. [10]

In an Italian real-world study of adults with Fabry disease, severe or fatal events were common over patients' lifetimes, and heart-related events made up a substantial share. Heart muscle thickening was frequently detected or worsened, and many patients were receiving Fabry-specific therapy, showing that meaningful cardiac risk can remain even with ongoing disease-directed care. [12]

For a specific non-classical Fabry gene variant (p.I319T), most of the disease impact was on the heart and appeared later in life, especially in men. This study also reported that most participants had traditional cardiovascular risk factors, and higher levels of a Fabry-related blood marker (lysoGb3) tracked with greater chance of later cardiac complications in women, while women with low levels rarely had complications. [11]

In a heart failure cohort with very high ejection fraction, patients whose heart failure was driven by an intrinsic heart muscle problem (a group that included Fabry disease) had worse outcomes than those whose heart failure was mainly due to loading conditions like high blood pressure. In this analysis, the group classification predicted outcomes even after adjustment, while one commonly used heart failure blood test (NT-proBNP) was not an independent predictor. [13]

One case report described a man with classic Fabry disease who had rapid worsening of coronary artery disease despite controlled traditional risk factors and ongoing enzyme replacement therapy. Detailed artery imaging showed multiple high-risk plaques and blood tests suggested inflammation, raising the possibility that Fabry-related factors may contribute to atherosclerosis in some individuals. [14]

For patients and caregivers, these studies suggest that estimating heart risk in Fabry disease may increasingly rely on a bundle of information (sex, the specific gene variant, ECG changes, heart imaging changes such as thickening or scarring, and selected blood markers) rather than any single test. Much of this work is still about improving how clinicians describe and track risk over time, and some results apply only to certain variants or specific clinical situations. Important uncertainties remain, including how well newer multi-part prediction models perform in other hospitals and populations, and how often inflammation or accelerated coronary disease occurs across Fabry disease more broadly (since a case report reflects one person).

This month, research beyond the heart and kidneys highlighted that Fabry disease can affect everyday safety, eye structure and autonomic (automatic body) responses, and breathing tests, sometimes even when a person does not feel clear symptoms. The strongest evidence came from a large national study on injuries, while the eye and lung reports were smaller and more exploratory. Overall, these papers suggest that Fabry-related nerve and tissue changes may show up in multiple body systems and can complicate how new symptoms are interpreted. [15] [16] [17]

In a nationwide study from Taiwan, adults with Fabry disease had a higher rate of injuries than matched people without Fabry disease. The increase was mainly driven by motor vehicle traffic accidents and falls, and the risk was higher in winter and in people with more other health conditions. [15]

In a small prospective cross-sectional study comparing Fabry disease patients with healthy controls, the Fabry group showed reduced maximal redilation velocity (a pupil response that can reflect autonomic function) and thinner corneal epithelium in the peripheral cornea. Higher plasma lyso-Gb3 (a Fabry-related blood marker) was linked to thinner corneal epithelium, but it was not clearly linked to the pupil test results or tear and eyelid gland measures in this study. [16]

A case report described one 39-year-old man with genetically confirmed Fabry disease who had a mixed pattern on breathing tests despite no respiratory symptoms, and chest imaging did not show emphysema. The report emphasized that smoking history can lead clinicians to suspect chronic obstructive pulmonary disease (COPD), but Fabry-related changes in the airways may also explain abnormal lung function tests in some people. [17]

For patients and caregivers, these studies add context for why some people with Fabry disease may experience issues that are not primarily heart- or kidney-related, such as injury events, eye surface or cornea changes, and abnormal breathing tests. The injury study is the most reliable signal because it included many patients, but it cannot explain exactly why injuries were more common or which individuals are most at risk. The eye and lung studies help describe possible body changes and measurement tools, but they are early-stage and do not yet show how well these findings predict symptoms or long-term outcomes.

Across these studies, researchers focused on biology and tool-building rather than testing treatments in people. The overall direction was toward (1) ways to increase alpha-galactosidase A activity in cells, (2) better understanding what alpha-galactosidase A may interact with inside kidney-related cells, and (3) higher-resolution methods to measure where stored fat builds up in heart tissue in Fabry disease models.

In a cell-based lab study, folic acid increased alpha-galactosidase A (AGLA) gene signal, protein amount, and enzyme activity in a concentration-dependent pattern in human lymphoblastoid cell lines, including one cell line from a person with Fabry disease. The same study also reported that folic acid increased activity of recombinant (lab-made) AGLA by raising the maximum reaction rate without changing substrate binding, and it did not raise activity of other lysosomal enzymes that were tested. [18]

That folic acid study also looked at 1-deoxygalactonojirimycin (DGJ), a small-molecule chaperone used in Fabry research and care, and found that folic acid augmented DGJ-restored AGLA activity in the single patient-derived cell line studied. The authors did not find a difference in DNA methylation in one tested region of the GLA gene, so the mechanism for higher AGLA levels was not explained by that specific methylation change. [18]

In kidney podocyte cells grown in the lab, a proximity-labeling proteomics approach suggested alpha-galactosidase A (AGAL) is near, or potentially interacts with, a set of proteins enriched for extracellular matrix-related pathways. One protein, Gal-3BP, was confirmed as an AGAL interactor using a separate pull-down method, raising the possibility that AGAL has roles beyond breaking down stored fats inside lysosomes. [19]

In mouse heart tissue, another preclinical study developed an automated way to align two imaging methods so researchers could map globotriaosylceramide (Gb3) and related lipids at very fine spatial resolution. Using this workflow, the study showed higher Gb3 content in mice with GLA knockout plus human Gb3 synthase overexpression compared with GLA knockout alone and wild-type mice, and it visualized that Gb3 was not evenly distributed across the tissue. [20]

For patients and caregivers, these results mainly add background knowledge and research tools rather than changing care now, because all three studies were done in cells or in animals. The folic acid results suggest a possible way to boost enzyme activity in lab systems, including alongside DGJ, but whether this translates to meaningful changes in Gb3 storage or to clinical benefit and safety in people is unknown. The podocyte protein-interaction work and the high-resolution heart-tissue imaging may help researchers better connect enzyme biology to kidney and heart damage over time, but many identified protein links and tissue-mapping patterns still need confirmation in more disease-relevant models and in human samples.